Publication | Closed Access
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2.9K
Citations
8
References
2002
Year
Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
| Year | Citations | |
|---|---|---|
Page 1
Page 1